• In late January 2026, a U.S. District Judge ruled that Moderna must face a US$5 billion patent-infringement lawsuit over its COVID-19 vaccine technology, denying the company’s attempt to claim government immunity for most of the doses supplied.
• The case centers on whether Moderna’s Spikevax formulation used lipid nanoparticle molar ratios covered by Arbutus and Genevant patents, making it a closely watched test of how intellectual property rights apply to rapidly developed pandemic-era biotech innovations.
• We’ll examine how this high-stakes patent trial, particularly the dispute over lipid nanoparticle technology, could reshape Moderna’s broader investment narrative.

We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

What Is Moderna's Investment Narrative?

To own Moderna today, you have to believe its mRNA platform and expanding pipeline can ultimately justify ongoing losses and a still-rich sales multiple, even after a very large three-year drawdown. The core near term catalysts remain execution in respiratory vaccines, progress in oncology programs like the Merck-partnered melanoma vaccine, and clarity on when revenue can scale enough to narrow losses. The new US$5 billion LNP patent trial now sits among the top risks: beyond potential damages, an adverse ruling could weigh on how investors view the durability of Moderna’s COVID-era IP and cash flows. By contrast, the appointment of experienced immunotherapy developer David Berman as Chief Development Officer looks more like a medium term pipeline story than something that changes the immediate earnings trajectory.

However, the US$5 billion patent claim is exactly the kind of risk investors should not ignore. Moderna's share price has been on the slide but might be up to 8% below fair value. Find out if it's a bargain.

Exploring Other Perspectives

Twenty two fair value views from the Simply Wall St Community span roughly US$38 to US$175 per share, showing wide disagreement on Moderna’s upside as investors weigh pipeline potential against the new US$5 billion patent overhang.

Explore 22 other fair value estimates on Moderna - why the stock might be worth over 4x more than the current price!

Build Your Own Moderna Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Moderna research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Moderna research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Moderna's overall financial health at a glance.

Want Some Alternatives?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 28 companies in the world exploring or producing it. Find the list for free.
• Explore 22 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.